Post by Symeres

Today Symeres and Ambagon Therapeutics have announced a collaboration to advance understanding in colorectal cancer. This approach will explore a new class of small molecules, known as molecular glues for potential use in colorectal cancer. Molecular glues are an emerging therapeutic modality that offer an alternative to conventional inhibitors or activators. The project will focus on the evaluation of ternary complex kinetics using surface plasmon resonance (ResidenceTimer™), alongside cellular assays to assess functional impact on disease-relevant pathways. "By combining Ambagon’s molecular glue technology with our translational research capabilities, we aim to generate meaningful insights to accelerate preclinical development across a variety of therapeutic conditions.” said Jorg Benningshof, Managing Director Oncolines B.V., a Symeres company. Christian Ottmann, Co-founder and CSO Ambagon Therapeutics added: “This collaboration enables us to deepen our understanding of how molecular glues can modulate disease-relevant pathways in colorectal cancer. Working with Symeres provides access to robust validation platforms that are critical for progressing our pipeline.” Read more about this exciting collaboration 👉https://lnkd.in/eD8Dbqwg #CDMO #Oncology #Biotech #Innovation